2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2672

Serum Vitamin D Levels and Its Effect on Disease Activity and Fatigue in Systemic Lupus Erythematosus Patients
Abstract Number: 2673

Different Risk Profiles for Development of Steroid-Related and Steroid-Unrelated Damage in Early Diagnosed SLE: Results from the Italian Multicenter Early Lupus Project Inception Cohort
Abstract Number: 2674

Identifying Phenotype Clusters in Systemic Lupus Erythematosus By Damage Cluster
Abstract Number: 2675

Age-Related Metabolic Changes Underlie Pro-Inflammatory Lineage Specification and Contribute to Therapeutic Responsiveness to Mechanistic Target of Rapamycin Blockade in SLE
Abstract Number: 2676

SLE Patients with No Organ Damage Might Benefit More from Belimumab Treatment
Abstract Number: 2677

A Systematic Review Examining the Association between Organ Damage and Health-Related Quality of Life in Systemic Lupus Erythematosus
Abstract Number: 2678

Integrated Safety Profile of Atacicept from All Clinical Studies to Date
Abstract Number: 2679

Glucocorticoids Withdrawal in Systemic Lupus Erythematosus: Are Remission and Low Disease Activity Reliable Starting Points for Stopping Therapy? a Real-Life Experience
Abstract Number: 2680

Activation Towards Health Self-Management in Patients with Systemic Lupus Erythematosus
Abstract Number: 2681

Lupus Primary Care Management Practices
Abstract Number: 2682

Novel Antibody Against Commensal Bacterial Antigen in Prediction of the Response of Rituximab in Systemic Lupus Erythematosus
Abstract Number: 2683

Selective Expansion and Targeting of FoxP3+CD127lo Regulatory T Cells By Low-Dose IL-2 Therapy in Active SLE
Abstract Number: 2684

Type I IFN, TLR7, MHC Class I, B Cell and OX40 Pathways Suppressed By Anifrolumab (anti-type I IFN receptor) in Moderate to Severe SLE Patients
Abstract Number: 2685

Interferon-Inducible Gene Expression Kit As a Potential Diagnostic Test for Anifrolumab: Analytical Validation for Use in Clinical Trials
Abstract Number: 2686

Podocyte Foot Process Width Is a Prediction Marker for Complete Renal Remission at 6 and 12 Months after Induction Therapy in Lupus Nephritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].